| 000 | 01351 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250513155814.0 | ||
| 264 | 0 | _c19981216 | |
| 008 | 199812s 0 0 eng d | ||
| 022 | _a0959-8049 | ||
| 024 | 7 |
_a10.1016/s0959-8049(98)00002-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHillner, B E | |
| 245 | 0 | 0 |
_aCost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma. _h[electronic resource] |
| 260 |
_bEuropean journal of cancer (Oxford, England : 1990) _cJul 1998 |
||
| 300 |
_aS18-21 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xeconomics |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aCombined Modality Therapy _xeconomics |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aHealth Care Costs |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xeconomics |
| 650 | 0 | 4 |
_aMelanoma _xtherapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 |
_aSkin Neoplasms _xtherapy |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aVirginia |
| 773 | 0 |
_tEuropean journal of cancer (Oxford, England : 1990) _gvol. 34 Suppl 3 _gp. S18-21 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0959-8049(98)00002-1 _zAvailable from publisher's website |
| 999 |
_c9812513 _d9812513 |
||